« Return to News | Clinical Intelligence

Millennium expands cancer pact with Seattle Genetics

Friday, March 18, 2011 01:43 PM

Takeda's Millennium has expanded its antibody-drug conjugate deal with Seattle Genetics, paying an undisclosed fee to exercise an option to designate a second antigen target outlined in their 2009 collaboration, according to Biosmart.

Seattle Genetics has had positive mid-stage trial results for SGEN-35, or brentuximab vedotin. The therapy is considered a leader among a new type of cancer drug that combines an antibody for targeting cancer and a linker that drops a cancer-killing agent right on target, allowing for targeted, high-dose blasts of toxic agents. Late last year new data put Seattle Genetics and its partner Takeda on target to gain a potential approval for marketing the drug this year.

"This expansion of our ADC collaboration demonstrates Millennium's continuing commitment to our ADC technology," stated Eric Dobmeier, chief business officer at Seattle Genetics. "We currently have 10 ongoing ADC collaborations and have generated nearly $150 million from ADC licensing deals to date. In addition, there are 11 ADCs in clinical development utilizing Seattle Genetics' technology."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.